secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001193125-24-049197
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics FY 2023 net loss $34.1M; cash into Q4 2025; SNS-101 data due Q2 2024
--------------------------------------------------------------------------------

- Net loss $34.1M in FY2023 vs $48.6M in FY2022; R&D expense fell to $18.3M from $30.4M.
- Cash, equivalents, and marketable securities $65.8M at Dec 31, 2023 (down from $107.1M); runway now into Q4 2025.
- SNS-101 Phase 1/2: topline efficacy/biomarker data expected Q2 2024 (ahead of prior guidance); no DLTs in 33 patients.
- Resource realignment: paused preclinical TMAb programs (SNS-102, SNS-103, SNS-201) to focus on SNS-101.
- Appointed Ron Weitzman as part-time CMO (Jan 2024) and Stephanie Krebs as CBO (Nov 2023).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312524049197/0001193125-24-049197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312524049197/d770175d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-049197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer